However, activated platelets bound avidly to HUVEC with single or clumped platelets coating the endothelial cells (Fig

However, activated platelets bound avidly to HUVEC with single or clumped platelets coating the endothelial cells (Fig.2B). P-selectin, and platelet-endothelial cell adhesion molecule (PECAM)-1 did not reduce platelet adhesion to HUVEC, blockade of platelet GPIIbIIIa by antibodies or Arg-Gly-Asp (RGD) peptides markedly decreased adhesion. Moreover, when platelets were treated with blocking antibodies to GPIIbIIIa-binding adhesive proteins, including fibrinogen and fibronectin, and von Willebrand factor (vWF), platelet binding was also reduced markedly. Addition of fibrinogen, fibronectin, or vWF further increased platelet Atractylenolide III adhesion, indicating that both endogenous platelet-exposed and exogenous adhesive proteins can participate in the binding process. Evaluation of the HUVEC receptors revealed predominant involvement of intercellular adhesion molecule (ICAM)-1 and v3integrin. Blockade of these two receptors by antibodies decreased platelet binding significantly. Also, there was evidence that a component of platelet adhesion was mediated by endothelial GPIb. Blockade of 1integrins, E-selectin, P-selectin, PECAM-1, vascular cell adhesion molecule (VCAM)-1 and different matrix proteins on HUVEC did not impact platelet adhesion. In conclusion, we show that activated platelet binding to HUVEC monolayers is usually mediated by a GPIIbIIIa-dependent bridging mechanism including platelet-bound adhesive proteins and the endothelial cell receptors ICAM-1, v3integrin, and, to a lesser extent, GPIb. Although the pathophysiologic effects of activated platelets in blood circulation are not yet fully understood, it is well established that increased platelet activation is usually associated with an enhanced risk of thrombotic complications in different clinical disorders, such as diabetes, preeclampsia, unstable angina, peripheral vascular disease, and stroke and after angioplastic and fibrinolytic therapy (1). Because activated, but not resting, platelets have been shown to adhere IL15RB to intact endothelium, it has been suggested that platelet thrombi may also occur in the absence of endothelial cell denudation, particularly in the microvasculature (25). However, while the platelet receptors involved in aggregate formation and matrix adhesion have been analyzed extensively, the pathways responsible for the conversation of platelets and the endothelium are not well characterized. So far, three different platelet receptors have been reported to be involved in the binding to endothelium. Rolling of activated platelets on high endothelial venules was found to depend primarily on platelet P-selectin (IIb3; CD62P; 6), whereas firm adhesion to human saphenous vein Atractylenolide III endothelial cells was inhibited by anti-GPIIbIIIa (CD41a/ CD61) antibodies and RGD peptides (7). Furthermore, it has been shown that platelet-sialylated glycoproteins may, at least in part, be responsible for the increased adhesion of platelets from diabetics to bovine valvular endothelial cells (8). Similarly, several unique endothelial cell molecules have been reported to be involved in the binding of resting and activated platelets. Both endothelial-sialylated glycoproteins (6), as well as P-selectin on activated endothelium (9), have been proposed to mediate platelet rolling. With human umbilical vein endothelial cells (HUVEC)1infected with herpes virus or stimulated with IL-1 or plasma made up of chemotherapeutic drugs, platelet adhesion was effectively inhibited by antibodies to endothelial von Willebrand factor (vWF) and v3integrin (CD51/CD61), respectively (1012). Moreover, a recent in vivo study has presented evidence that plateletendothelial cell adhesion molecule-1 (PECAM-1; CD31) on endothelial cells may contribute to platelet adhesion and aggregation at a site of injured but not denuded endothelium (13). Thus, this study was designed to further clarify the role of the different receptors that have Atractylenolide III been implicated in the adherence conversation of platelets with endothelial cells. Because both resting and activated platelets adhere primarily to matrix proteins, rather than to endothelial cells, many investigators have used fixed endothelial cells in the adhesion assay in an attempt to maintain total confluence. However, fixation can alter the receptor function and does not exclude the involvement of matrix proteins exposed by small intercellular gaps or expressed around the endothelial cells themselves. Hence, to avoid this problem, platelet binding to HUVEC was decided in suspension using circulation cytometry. Our results show that thrombin-activated platelets bind to HUVEC by a GPIIbIIIa-dependent bridging mechanism including platelet-bound adhesive proteins, including Atractylenolide III fibrinogen, fibronectin, and vWF. Importantly, activated platelet binding did not involve endothelial cellassociated adhesive proteins such as collagen IV, fibronectin, and vWF, but instead used intercellular adhesion molecule-1 (ICAM-1; CD54) and v3integrin. In addition, we also found evidence for the involvement of endothelial GPIb (CD42b). Thus, these endothelial adhesion molecules may contribute to the recruitment of activated platelets to intact endothelium and, consequently, to the formation of intravascular platelet aggregates, thereby Atractylenolide III promoting thrombotic processes. == Materials and Methods == == Endothelial Cell Culture. == HUVEC were obtained by collagenase treatment of umbilical cord veins as previously explained (14). Cells were cultured on gelatin-coated dishes and propagated in RPMI 1640 medium (BioWhittaker,.